Publicacións en colaboración con investigadores/as de Hospital Universitario 12 de Octubre (21)

2024

  1. Practical use of new therapies for the management of dyslipidaemias. Consensus SEC/SEA/SEEN/SEMFYC/SEMERGEN/SEMG/SEN/SEACV/S.E.N.

    REC: CardioClinics, Vol. 59, Núm. 4, pp. 310-321

2022

  1. Outcomes and predictive value of the 2MACE score in patients with atrial fibrillation treated with rivaroxaban in a prospective, multicenter observational study: The EMIR study

    Cardiology Journal, Vol. 29, Núm. 4, pp. 601-609

  2. Use of rivaroxaban attenuates renal function impairment in patients with atrial fibrillation: insights of the EMIR study

    European Journal of Clinical Investigation

2021

  1. Chronic coronary syndrome: Overcoming clinical practice guidelines. the role of the compass strategy

    Current Cardiology Reviews, Vol. 17, Núm. 3, pp. 364-375

  2. Thromboembolic and bleeding events with rivaroxaban in clinical practice in Spain: Impact of inappropriate doses (the EMIR study)

    Journal of Comparative Effectiveness Research, Vol. 10, Núm. 7, pp. 583-593

2020

  1. Patients with a high cardiovascular risk and atrial fibrillation: the role of rivaroxaban

    Revista Espanola de Cardiologia Suplementos, Vol. 20, pp. 30-38

  2. Prevalence of office and ambulatory hypotension in treated hypertensive patients with coronary disease

    Hypertension Research, Vol. 43, Núm. 7, pp. 696-704

2016

  1. Cambios en los objetivos terapéuticos y grado de control de la hipertensión arterial: nuevas evidencias

    Hipertensión y riesgo vascular, Vol. 33, Núm. 2, pp. 63-68

2008

  1. High doses of lercanidipine are better tolerated than other dihydropyridines in hypertensive patients with metabolic syndrome: Results from the TOLERANCE study

    International Journal of Clinical Practice, Vol. 62, Núm. 5, pp. 723-728

  2. Tolerability of high doses of lercanidipine versus high doses of other dihydropyridines in daily clinical practice: The TOLERANCE study

    Cardiovascular Therapeutics, Vol. 26, Núm. 1, pp. 2-9

2007

  1. Antihypertensive effectiveness of lercanidipine administered using an electronic pillbox compared with usual care in a cohort of mild-to-moderately hypertensive patients: The ELECTRA study

    Therapy, Vol. 4, Núm. 4, pp. 433-440

  2. Cardiovascular risk profile and risk stratification of the hypertensive population attended by general practitioners and specialists in Spain. The CONTROLRISK study

    Journal of Human Hypertension, Vol. 21, Núm. 6, pp. 479-485

  3. Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: The OLMEBEST study

    Clinical Drug Investigation, Vol. 27, Núm. 8, pp. 545-558

  4. Evolution of blood pressure control in Spain [2]

    Journal of Hypertension

2006

  1. Effect of NSAID on blood pressure among hypertensive patients with a high cardiovascular risk

    Anales de Medicina Interna, Vol. 23, Núm. 9

  2. Prevalence of renal insufficiency in individuals with hypertension and obesity/overweight: The FATH study

    Journal of the American Society of Nephrology

  3. The effectiveness and tolerability of lercanidipine is independent of body mass index or body fat percent. The LERZAMIG study

    British Journal of Cardiology, Vol. 13, Núm. 6, pp. 434-440

2005

  1. Estudio PREVENCAT: Control del riesgo cardiovascular en atención primaria

    Medicina Clinica, Vol. 124, Núm. 11, pp. 406-410

2000

  1. Renal implications of the renin-angiotensin-aldosterone system blockade in heart failure

    Journal of Hypertension, Vol. 18, Núm. 11, pp. 1545-1551

1999

  1. The kidney in heart failure: Role of angiotensin II

    Current Opinion in Nephrology and Hypertension, Vol. 8, Núm. 2, pp. 153-156